Literature DB >> 24563620

Paradoxically augmented anti-tumorigenic action of proton pump inhibitor and GastrininAPCMin/+ intestinal polyposis model.

Young-Min Han1, Ki Baik Hahm1, Jong-Min Park2, Sung Pyo Hong3, Eun-Hee Kim1.   

Abstract

Though long-term administration of proton pump inhibitor (PPI) imposed the risk of gastrointestinal track tumorigenesis by accompanied hypergastrinemia, no overt increases of colon cancer risk were witnessed after a long-term cohort study. Our recent investigation revealed that PPI prevented colitis-associated carcinogenesis through anti-inflammatory, anti-oxidative, and anti-mutagenic mechanisms in spite of hypergastrinemia. Therefore, we hypothesized that PPI might either antagonize the trophic action of gastrin on gastrointestinal tumorigenesis or synergize to exert augmented anti-tumorigenic actions. We challenged APCMin/+ mice with gastrin, PPI, PPI and gastrin together for 10 weeks and counted intestinal polyposis accompanied with molecular changes. Gastrin significantly increased intestinal polyposis, but combination of PPI and gastrin markedly attenuated intestinal polyposis compared to gastrin-promoted APCMin/+ mice (P<.001), in which significant β-catenin phosphorylation and inhibition of β-catenin nuclear translocation were observed with PPI alone or combination of PPI and gastrin, whereas gastrin treatment significantly increased β-catenin nuclear translocation. Significant footprints of apoptosis, G0/G1 accumulation, inactivation of p38 and extracellular signal-regulated kinase, decreased expressions of CD31, and inhibition of tumor necrosis factor-α and cyclooxygenase-2 were noted in the combination group. In vitro investigations were similar to in vivo findings as shown that PPI treatment inhibited the binding of gastrin to its receptor, inactivated β-catenin-associated signaling including Tcf/Lef and glycogen synthase kinase β, and paradoxically inhibited β-catenin-associated proliferative activities. Our investigations explain why colon cancer risk has not increased despite long-term use of PPIs and provide a rationale for using PPI to achieve anti-tumorigenesis beyond acid suppression.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24563620      PMCID: PMC3924549          DOI: 10.1593/neo.131510

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  37 in total

1.  Chronic proton pump inhibitor therapy and the risk of colorectal cancer.

Authors:  Yu-Xiao Yang; Sean Hennessy; Kathleen Propert; Wei-Ting Hwang; Alireza Sedarat; James D Lewis
Journal:  Gastroenterology       Date:  2007-06-20       Impact factor: 22.682

Review 2.  Perturbation of cell cycle regulators in human cancer.

Authors:  I Palmero; G Peters
Journal:  Cancer Surv       Date:  1996

3.  Gastrin suppresses growth of CCK2 receptor expressing colon cancer cells by inducing apoptosis in vitro and in vivo.

Authors:  Susanne Müerköster; Anett Isberner; Alexander Arlt; Maike Witt; Babette Reimann; Ewelina Blaszczuk; Veronika Werbing; Ulrich R Fölsch; Frank Schmitz; Heiner Schäfer
Journal:  Gastroenterology       Date:  2005-09       Impact factor: 22.682

Review 4.  Role of gastrin as a trophic hormone.

Authors:  J H Walsh
Journal:  Digestion       Date:  1990       Impact factor: 3.216

Review 5.  Gastrin, CCK, signaling, and cancer.

Authors:  E Rozengurt; J H Walsh
Journal:  Annu Rev Physiol       Date:  2001       Impact factor: 19.318

Review 6.  Signaling pathways mediating gastrin's growth-promoting effects.

Authors:  R R Yassin
Journal:  Peptides       Date:  1999       Impact factor: 3.750

7.  Novel action of gastric proton pump inhibitor on suppression of Helicobacter pylori induced angiogenesis.

Authors:  M Yeo; D-K Kim; S U Han; J E Lee; Y B Kim; Y K Cho; J H Kim; S W Cho; K-B Hahm
Journal:  Gut       Date:  2005-08-26       Impact factor: 23.059

Review 8.  Gastrin as a growth factor in the gastrointestinal tract.

Authors:  T J Koh; D Chen
Journal:  Regul Pept       Date:  2000-09-25

9.  Acid pH in tumors and its potential for therapeutic exploitation.

Authors:  I F Tannock; D Rotin
Journal:  Cancer Res       Date:  1989-08-15       Impact factor: 12.701

10.  Trophic effects of gastrin on colorectal neoplasms in the rat.

Authors:  D B McGregor; R D Jones; D A Karlin; M M Romsdahl
Journal:  Ann Surg       Date:  1982-02       Impact factor: 12.969

View more
  9 in total

1.  A retrospective analysis of the role of proton pump inhibitors in colorectal cancer disease survival.

Authors:  C Graham; C Orr; C S Bricks; W M Hopman; N Hammad; R Ramjeesingh
Journal:  Curr Oncol       Date:  2016-12-21       Impact factor: 3.677

2.  Acid suppression therapy and allergic reactions.

Authors:  Eva Untersmayr
Journal:  Allergo J Int       Date:  2015-12

3.  The efficacy of human placenta-derived mesenchymal stem cells on radiation enteropathy along with proteomic biomarkers predicting a favorable response.

Authors:  Young-Min Han; Jong-Min Park; Yong Soo Choi; Hee Jin; Yun-Sil Lee; Na-Young Han; Hookeun Lee; Ki Baik Hahm
Journal:  Stem Cell Res Ther       Date:  2017-05-02       Impact factor: 6.832

Review 4.  Rethinking the Combination of Proton Exchanger Inhibitors in Cancer Therapy.

Authors:  Elisabetta Iessi; Mariantonia Logozzi; Davide Mizzoni; Rossella Di Raimo; Claudiu T Supuran; Stefano Fais
Journal:  Metabolites       Date:  2017-12-23

5.  Administration of Steamed and Freeze-Dried Mature Silkworm Larval Powder Prevents Hepatic Fibrosis and Hepatocellular Carcinogenesis by Blocking TGF-β/STAT3 Signaling Cascades in Rats.

Authors:  Da-Young Lee; Sun-Mi Yun; Moon-Young Song; Sang-Deok Ji; Jong-Gon Son; Eun-Hee Kim
Journal:  Cells       Date:  2020-02-28       Impact factor: 6.600

6.  Proton pump inhibitors and colorectal cancer: A systematic review.

Authors:  Agastya Patel; Piotr Spychalski; Magdalena Antoszewska; Jaroslaw Regula; Jarek Kobiela
Journal:  World J Gastroenterol       Date:  2021-11-28       Impact factor: 5.742

7.  Evidence-based support for the use of proton pump inhibitors in cancer therapy.

Authors:  Stefano Fais
Journal:  J Transl Med       Date:  2015-11-24       Impact factor: 5.531

8.  Xanthohumol prevents dextran sulfate sodium-induced colitis via inhibition of IKKβ/NF-κB signaling in mice.

Authors:  Jae-Min Cho; Sun-Mi Yun; Young-Ho Choi; Jinyuk Heo; Nam-Jung Kim; Seok-Ho Kim; Eun-Hee Kim
Journal:  Oncotarget       Date:  2017-12-12

9.  Cyanidin Chloride Induces Apoptosis by Inhibiting NF-κB Signaling through Activation of Nrf2 in Colorectal Cancer Cells.

Authors:  Da-Young Lee; Sun-Mi Yun; Moon-Young Song; Kiwon Jung; Eun-Hee Kim
Journal:  Antioxidants (Basel)       Date:  2020-03-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.